QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report “Laboratory-Developed Testing Service- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Laboratory-Developed Testing Service market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Laboratory-Developed Testing Service was estimated to be worth US$ 6624 million in 2025 and is projected to reach US$ 14921 million, growing at a CAGR of 12.3% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6699058/laboratory-developed-testing-service
Laboratory-Developed Testing Service Market Summary
Laboratory-developed testing service refer to medical testing services designed, developed, and validated—and subsequently performed in-house—by qualified clinical laboratories or third-party medical testing institutions. Typically, these services do not rely on commercially registered, standardized in vitro diagnostic (IVD) kits; instead, sample testing is conducted based on methodologies, testing workflows, quality control systems, and result interpretation capabilities established internally by the laboratory. LDTs are frequently utilized in fields such as oncology genomics, genetic disease screening, rare disease detection, pathogen identification, pharmacogenomics, companion diagnostics, and protein/metabolite biomarker analysis. Characterized by their high flexibility, LDTs are capable of addressing emerging or niche clinical needs; however, they impose rigorous requirements regarding laboratory accreditation, methodological validation, quality control, data analysis, and regulatory compliance management.
According to the new market research report “Global Laboratory-Developed Testing Service Market Report 2026-2032”, published by QYResearch, the global Laboratory-Developed Testing Service market size is projected to reach USD 13.81 billion by 2032, at a CAGR of 12.2% during the forecast period.
Figure00001. Laboratory-Developed Testing Services Value Chain
Figure00002. Global Laboratory-Developed Testing Service Market Size (US$ Million), 2021-2032
Above data is based on report from QYResearch: Global Laboratory-Developed Testing Service Market Report 2026-2032 (published in 2026). If you need the latest data, plaese contact QYResearch.
Figure00003. Global Laboratory-Developed Testing Service Top 14 Players Ranking and Market Share (Ranking is based on the revenue of 2025, continually updated)
Above data is based on report from QYResearch: Global Laboratory-Developed Testing Service Market Report 2026-2032 (published in 2026). If you need the latest data, plaese contact QYResearch.
According to QYResearch Top Players Research Center, the global key manufacturers of Laboratory-Developed Testing Service include Quest Diagnostics, Thermo Fisher, Waters Corporation, Roche, Illumina, Qiagen, SRL, BML, Eurofins, Guardant Health, etc. In 2025, the global top five players had a share approximately 53.0% in terms of revenue.
Figure00004. Laboratory-Developed Testing Service, Global Market Size, Split by Product Segment
Based on or includes research from QYResearch: Global Laboratory-Developed Testing Service Market Report 2026-2032.
In terms of product type, Molecular Diagnostics is the largest segment, hold a share of 30.6%,
Market Drivers:
1. Growing Demand for Precision Medicine and Personalized Therapy.
The primary driving force behind LDT services stems from the advancement of precision medicine—particularly in fields such as targeted oncology therapies, immunotherapy, genetic disease diagnostics, pharmacogenomics, and companion diagnostics. Many clinical challenges cannot be fully resolved through reliance solely on standardized in vitro diagnostic (IVD) kits; instead, laboratories must develop in-house testing assays tailored to specific disease types, mutation profiles, sample types, and clinical requirements. As the demand among physicians and patients for “genetically guided, biomarker-driven, and individualized therapeutic approaches” continues to rise, the value of LDT services in clinical decision-making is expected to grow even stronger. The global precision medicine market is likewise projected to expand, driven by advancements in genomics, the growing demand for personalized therapies, and innovations in diagnostic technologies.
2. Increased Demand for Testing in Oncology, Genetic Diseases, and Infectious Diseases.
LDTs are frequently employed in diagnostic scenarios involving high complexity or emerging diseases—such as oncology NGS panels, minimal residual disease (MRD) monitoring, genetic and rare disease screening, and pathogen drug-resistance gene detection. Cancer patients require genetic testing to identify suitable targeted therapies and immunotherapy regimens; patients with genetic or rare diseases require more flexible and customized testing panels; and the field of infectious diseases necessitates the rapid development of diagnostic methods to address newly emerging pathogens or novel drug-resistance mechanisms. Consequently, the rising global disease burden—coupled with the increasing complexity of clinical diagnostics—will continue to expand the scope of applications for LDT services. Persistence Market Research has also identified the demand for personalized/precision medicine, alongside the rising incidence of cancer, infectious diseases, and genetic disorders, as key drivers of the LDT market.
3. Maturation of NGS, ddPCR, Mass Spectrometry, and Multi-omics Technologies.
Declining sequencing costs, automated sample processing, advanced bioinformatics analysis, and the maturation of high-throughput testing platforms have enabled laboratories to develop complex diagnostic assays at a lower cost. Next-Generation Sequencing (NGS) allows for the simultaneous detection of multiple genes, mutation types, and fusion events; droplet digital PCR (ddPCR) is ideally suited for detecting low-abundance mutations and monitoring MRD; mass spectrometry facilitates the measurement of drug concentrations, metabolites, and protein biomarkers; while multi-omics approaches drive advancements in disease subtyping and risk prediction. As these technological platforms continue to mature, the barriers to entry for laboratories developing new diagnostic assays will decrease, thereby accelerating the pace of product innovation and expanding the clinical coverage of LDT services.
4. Insufficient Coverage by Standardized IVD Kits. For many rare diseases, uncommon mutations, novel tumor markers, complex biomarkers, and specialized sample types, the testing demand is relatively low; consequently, commercial IVD enterprises may not be inclined to develop and register dedicated diagnostic kits. The primary advantage of Laboratory-Developed Tests (LDTs) lies in their inherent flexibility, enabling laboratories to rapidly establish testing protocols tailored to specific hospitals, physicians, or patient populations, thereby addressing “long-tail” clinical needs. This is particularly evident in the fields of new drug development, exploratory companion diagnostics, rare disease diagnosis, and the detection of emerging pathogens, where LDTs frequently precede the market launch of commercial IVD products.
5. Intensified Specialization and Division of Labor Between Hospitals and Third-Party Medical Laboratories.
The clinical laboratories of large-scale hospitals, third-party medical testing laboratories, and specialized molecular diagnostics companies are currently undergoing an upgrade—shifting their focus from routine testing toward high-complexity diagnostics. While hospitals possess direct access to clinical settings and patient samples, third-party laboratories excel in large-scale testing capabilities, automation, quality control, and data analytics; together, these two entities are driving the transition of LDT services from the realm of research validation into routine clinical application. As the development of specialized oncology centers, genetic counseling centers, maternal and child health centers, and regional medical testing hubs continues to advance, LDT services are poised to gradually emerge as a vital and integral component of high-end medical diagnostics.
Restraint:
1. High Regulatory Uncertainty
LDTs (Laboratory Developed Tests) inherently occupy a space straddling clinical laboratory services, in vitro diagnostic (IVD) products, and medical practice; consequently, regulatory approaches vary significantly across different countries and regions. In 2024, the U.S. FDA issued a final rule regarding LDTs, attempting to bring them under a more defined IVD regulatory framework; however, this rule was subsequently vacated by the courts. In 2025, the FDA issued a new rule reverting to the previous regulatory text, demonstrating that substantial uncertainty persists regarding LDT regulation. Such regulatory vacillation can impact companies’ long-term R&D investments, project registration strategies, commercialization timelines, and capital market expectations.
2. High Costs for Laboratory Accreditation, Quality Systems, and Compliance
While LDT services offer flexibility, they are critically dependent on high-standard laboratory management systems—encompassing personnel qualifications, assay validation, internal quality control, external quality assessment, sample tracking, report review, and data audit trails. In the United States, the Clinical Laboratory Improvement Amendments (CLIA) mandate that clinical laboratories obtain appropriate certification prior to testing human specimens and adhere to varying regulatory requirements based on the complexity of the assays performed; the more complex the assay method, the more stringent the compliance requirements. These high regulatory thresholds drive up costs associated with laboratory infrastructure development, personnel training, quality control, and auditing.
3. Protracted Cycle for Accumulating Clinical Evidence
LDT assays—particularly those involving oncology NGS (Next-Generation Sequencing), genetic disorders, rare diseases, MRD (Minimal Residual Disease) detection, and pharmacogenomics—cannot simply demonstrate technical feasibility (i.e., the ability to detect a specific marker). They must also demonstrate that the test results possess clear clinical utility regarding diagnosis, treatment selection, prognostic assessment, or therapeutic monitoring. The accumulation of such clinical evidence typically requires support from real-world data, prospective studies, physician consensus, and clinical practice guidelines. This process is both time-consuming and capital-intensive, creating significant translational barriers that hinder the progression of many novel assays from technical development to widespread clinical adoption.
4. Inadequate Reimbursement from Public and Private Payers
Many LDT assays carry high price tags, yet the reimbursement infrastructure remains underdeveloped—particularly for large-panel NGS, multi-omics assays, rare disease diagnostics, and recurrence monitoring tests. These categories frequently face challenges such as limited coverage by public health insurance, insufficient reimbursement rates from commercial insurers, and a high proportion of out-of-pocket costs for patients. Instability on the payer side directly impedes sample volume growth, making it difficult for companies to amortize fixed costs, while also dampening the enthusiasm of hospitals and physicians for adopting and promoting new diagnostic assays.
5. High Difficulty in Interpreting Test Results
The core barrier to entry for LDT services extends beyond mere laboratory testing to encompass bioinformatics analysis, database matching, variant interpretation, assessment of clinical significance, and report generation. Taking cancer and genetic disease testing as examples, a single gene variant may be associated with varying levels of evidence, differing interpretations within clinical guidelines, and distinct therapeutic recommendations. Consequently, if a laboratory lacks a specialized interpretation team, it is prone to issues such as inconsistent report quality, insufficient trust from physicians, and limited clinical adoption.
Opportunity:
1. Oncology NGS, MRD, and Liquid Biopsies Will Emerge as High-Value Growth Areas
Precision oncology continues to drive demand for genetic testing. Future growth will focus not only on guiding initial treatment decisions but also on assessing recurrence risk, monitoring minimal residual disease (MRD), tracking drug-resistance mutations, and dynamically monitoring treatment responses. Compared to tissue-based testing, liquid biopsies offer distinct advantages—being minimally invasive, repeatable, and well-suited for dynamic monitoring—making them one of the most commercially promising avenues within the Laboratory Developed Test (LDT) service sector.
2. Unmet Needs Persist in Genetic Diseases, Rare Diseases, and Newborn Screening
A vast number of genetic and rare diseases lack standardized commercial diagnostic kits; given the dispersed patient populations and the complexity of genetic variations involved, these conditions are ideally suited for the development of flexible testing solutions via the LDT model. As the costs of Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) decline, genetic counseling frameworks mature, and clinical awareness among physicians grows, the diagnosis of genetic diseases, carrier screening, testing for pediatric developmental disorders, and rare disease diagnostics are poised to become key drivers of long-term growth.
3. Expanding Opportunities for Pharmaceutical Partnerships and Companion Diagnostics Development
With the advancement of targeted therapies, immunotherapies, Antibody-Drug Conjugates (ADCs), cell therapies, and gene therapies, pharmaceutical companies require increasingly precise tools for patient stratification and efficacy monitoring. LDT laboratories can collaborate with pharmaceutical firms to conduct clinical trial sample analysis, biomarker validation, co-development of companion diagnostics, and real-world data studies—thereby evolving from mere testing service providers into comprehensive platforms supporting drug research and development.
4. AI and Automation Enhance Testing Efficiency and Reporting Value
Future LDT services will increasingly rely on automated sample processing, standardized bioinformatics workflows, AI-driven variant interpretation, dynamic knowledge base updates, and intelligent reporting systems. AI can boost the efficiency of variant annotation, minimize inter-analyst variability in manual interpretation, and assist laboratories in generating more standardized clinical reports. This will enhance the scalability of highly complex testing services, reduce unit costs, and significantly improve the clinical utility of diagnostic reports.
5. Growth of Hospital Co-development and Regional Central Laboratory Models
Many hospitals aspire to enhance their in-house precision diagnostics capabilities; however, establishing complex testing platforms independently often entails prohibitive costs. Consequently, collaborative models—such as “third-party laboratory + hospital co-development,” “regional central laboratories,” and “specialized testing centers”—are emerging as pivotal strategies. These models effectively align with clinical needs while enabling the shared utilization of equipment, personnel, quality control systems, and data platforms, thereby facilitating the expansion of LDT services beyond major metropolitan hubs and into broader regional healthcare markets.
The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.
The Laboratory-Developed Testing Service market is segmented as below:
By Company
Quest Diagnostics
Thermo Fisher
Waters Corporation
Roche
Illumina
Qiagen
Eurofins
Guardant Health
Adaptive Biotechnologies
Biodesix
Berry Oncology
Genetron Health
SRL
BML
Segment by Type
Rapid Testing (24–48 Hours)
Standard Testing (3–7 Days)
In-depth Analysis (7–14+ Days)
Segment by Application
Hospitals Laboratory
Clinical Research Organizations
Academic Institutes
Specialty Diagnostic Centers
Others
Each chapter of the report provides detailed information for readers to further understand the Laboratory-Developed Testing Service market:
Chapter 1: Introduces the report scope of the Laboratory-Developed Testing Service report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032)
Chapter 2: Detailed analysis of Laboratory-Developed Testing Service manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026)
Chapter 3: Provides the analysis of various Laboratory-Developed Testing Service market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032)
Chapter 5: Sales, revenue of Laboratory-Developed Testing Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032)
Chapter 6: Sales, revenue of Laboratory-Developed Testing Service in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Benefits of purchasing QYResearch report:
Competitive Analysis: QYResearch provides in-depth Laboratory-Developed Testing Service competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.
Industry Analysis: QYResearch provides Laboratory-Developed Testing Service comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.
and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.
Market Size: QYResearch provides Laboratory-Developed Testing Service market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.
Other relevant reports of QYResearch:
Global Laboratory-Developed Testing Service Market Outlook, In‑Depth Analysis & Forecast to 2032
Global Laboratory-Developed Testing Service Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
Global Laboratory-Developed Testing Service Market Research Report 2026
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
